# Anagram Therapeutics

> Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.

## Why it is interesting

Developing novel therapeutics is capital-intensive and high-risk, requiring sustained funding through clinical milestones. Anagram's raise provides the runway to advance its programs. - The reopening exit market improves biotech's funding outlook. - Investors are selectively backing validated science over platform hype. - Large therapeutics rounds anchor the broader life-sciences ecosystem. Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.

## Profile

- **Stage:** other
- **Status:** private
- **Industries:** ai-ml, healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-05-08

## Key facts

- Disclosed financing: $250M
- Covered in 1 Venture Capital Tracker article(s)

## Related articles

- https://venturecapitaltracker.com/2026-anagram-therapeutics-250m-biotech

---
Source: https://venturecapitaltracker.com/startup/anagram-therapeutics